Translational Multimodality Neuroimaging
Recently high-resolution, noninvasive, multimodality in-vivo molecular imaging with PET, SPECT, CT and MRI, employing fusion algorithms has revolutionized personalized medicine. However, novel discovery of specific radiopharmaceuticals (RPs) for the accurate diagnosis and effective treatment of prog...
Gespeichert in:
| Veröffentlicht in: | Current drug targets Jg. 18; H. 9; S. 1039 |
|---|---|
| 1. Verfasser: | |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Netherlands
01.07.2017
|
| Schlagworte: | |
| ISSN: | 1873-5592, 1873-5592 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Recently high-resolution, noninvasive, multimodality in-vivo molecular imaging with PET, SPECT, CT and MRI, employing fusion algorithms has revolutionized personalized medicine. However, novel discovery of specific radiopharmaceuticals (RPs) for the accurate diagnosis and effective treatment of progressive neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, drug addiction, and other cognitive impairments still remains a significant challenge.
The primary objective of this review is to highlight the clinical significance of multimodality fusion neuroimaging for the determination of: pharmacokinetics and pre-clinical development of radiopharmaceuticals (RPs); in-vivo monitoring of stem cell transplantation therapy; nicotinic acetylcholine receptors (nAChRs) investigations; and regional cerebral blood flow and glucose metabolism in cognitively-impaired subjects employing multimodality noninvasive PET, CT, MRI/MRS, and SPECT imaging.
Recent methodology to perform multimodality imaging employing computer-based fusion algorithms is provided with a primary emphasis on nanoSPECT/CT, PET-CT, and PET-MRI in experimental animals. Multimodality imaging is performed to detect CNS infections using 99mTc-HMPAO SPECT and 18F-FDG PET/CT. Furthermore, limitations of individual neuroimaging system, body movements due to cardiorespiratory activity, and co-registration of multimodality neuroimaging data are described.
Multimodality neuroimaging is clinically-significant because it emphasizes the importance of complementary imaging for theranostic applications and minimizes the inherent limitations of individual neuroimaging approach. However, it may increase the radiation dose to a susceptible pediatric population.
Future developments in specific RPs with minimum radiation exposure will facilitate early differential diagnosis, prevent, slowdown and/or cure neurodegenerative diseases, cardiovascular diseases, and cancer. Eventually, conventional and functional neuroimaging, combined with clinical, laboratory and - omics analyses will facilitate theranostics to accomplish the ultimate goal of personalized medicine. |
|---|---|
| AbstractList | Recently high-resolution, noninvasive, multimodality in-vivo molecular imaging with PET, SPECT, CT and MRI, employing fusion algorithms has revolutionized personalized medicine. However, novel discovery of specific radiopharmaceuticals (RPs) for the accurate diagnosis and effective treatment of progressive neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, drug addiction, and other cognitive impairments still remains a significant challenge.
The primary objective of this review is to highlight the clinical significance of multimodality fusion neuroimaging for the determination of: pharmacokinetics and pre-clinical development of radiopharmaceuticals (RPs); in-vivo monitoring of stem cell transplantation therapy; nicotinic acetylcholine receptors (nAChRs) investigations; and regional cerebral blood flow and glucose metabolism in cognitively-impaired subjects employing multimodality noninvasive PET, CT, MRI/MRS, and SPECT imaging.
Recent methodology to perform multimodality imaging employing computer-based fusion algorithms is provided with a primary emphasis on nanoSPECT/CT, PET-CT, and PET-MRI in experimental animals. Multimodality imaging is performed to detect CNS infections using 99mTc-HMPAO SPECT and 18F-FDG PET/CT. Furthermore, limitations of individual neuroimaging system, body movements due to cardiorespiratory activity, and co-registration of multimodality neuroimaging data are described.
Multimodality neuroimaging is clinically-significant because it emphasizes the importance of complementary imaging for theranostic applications and minimizes the inherent limitations of individual neuroimaging approach. However, it may increase the radiation dose to a susceptible pediatric population.
Future developments in specific RPs with minimum radiation exposure will facilitate early differential diagnosis, prevent, slowdown and/or cure neurodegenerative diseases, cardiovascular diseases, and cancer. Eventually, conventional and functional neuroimaging, combined with clinical, laboratory and - omics analyses will facilitate theranostics to accomplish the ultimate goal of personalized medicine. Recently high-resolution, noninvasive, multimodality in-vivo molecular imaging with PET, SPECT, CT and MRI, employing fusion algorithms has revolutionized personalized medicine. However, novel discovery of specific radiopharmaceuticals (RPs) for the accurate diagnosis and effective treatment of progressive neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, drug addiction, and other cognitive impairments still remains a significant challenge.BACKGROUNDRecently high-resolution, noninvasive, multimodality in-vivo molecular imaging with PET, SPECT, CT and MRI, employing fusion algorithms has revolutionized personalized medicine. However, novel discovery of specific radiopharmaceuticals (RPs) for the accurate diagnosis and effective treatment of progressive neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, drug addiction, and other cognitive impairments still remains a significant challenge.The primary objective of this review is to highlight the clinical significance of multimodality fusion neuroimaging for the determination of: pharmacokinetics and pre-clinical development of radiopharmaceuticals (RPs); in-vivo monitoring of stem cell transplantation therapy; nicotinic acetylcholine receptors (nAChRs) investigations; and regional cerebral blood flow and glucose metabolism in cognitively-impaired subjects employing multimodality noninvasive PET, CT, MRI/MRS, and SPECT imaging.OBJECTIVEThe primary objective of this review is to highlight the clinical significance of multimodality fusion neuroimaging for the determination of: pharmacokinetics and pre-clinical development of radiopharmaceuticals (RPs); in-vivo monitoring of stem cell transplantation therapy; nicotinic acetylcholine receptors (nAChRs) investigations; and regional cerebral blood flow and glucose metabolism in cognitively-impaired subjects employing multimodality noninvasive PET, CT, MRI/MRS, and SPECT imaging.Recent methodology to perform multimodality imaging employing computer-based fusion algorithms is provided with a primary emphasis on nanoSPECT/CT, PET-CT, and PET-MRI in experimental animals. Multimodality imaging is performed to detect CNS infections using 99mTc-HMPAO SPECT and 18F-FDG PET/CT. Furthermore, limitations of individual neuroimaging system, body movements due to cardiorespiratory activity, and co-registration of multimodality neuroimaging data are described.METHODRecent methodology to perform multimodality imaging employing computer-based fusion algorithms is provided with a primary emphasis on nanoSPECT/CT, PET-CT, and PET-MRI in experimental animals. Multimodality imaging is performed to detect CNS infections using 99mTc-HMPAO SPECT and 18F-FDG PET/CT. Furthermore, limitations of individual neuroimaging system, body movements due to cardiorespiratory activity, and co-registration of multimodality neuroimaging data are described.Multimodality neuroimaging is clinically-significant because it emphasizes the importance of complementary imaging for theranostic applications and minimizes the inherent limitations of individual neuroimaging approach. However, it may increase the radiation dose to a susceptible pediatric population.RESULTSMultimodality neuroimaging is clinically-significant because it emphasizes the importance of complementary imaging for theranostic applications and minimizes the inherent limitations of individual neuroimaging approach. However, it may increase the radiation dose to a susceptible pediatric population.Future developments in specific RPs with minimum radiation exposure will facilitate early differential diagnosis, prevent, slowdown and/or cure neurodegenerative diseases, cardiovascular diseases, and cancer. Eventually, conventional and functional neuroimaging, combined with clinical, laboratory and - omics analyses will facilitate theranostics to accomplish the ultimate goal of personalized medicine.CONCLUSIONFuture developments in specific RPs with minimum radiation exposure will facilitate early differential diagnosis, prevent, slowdown and/or cure neurodegenerative diseases, cardiovascular diseases, and cancer. Eventually, conventional and functional neuroimaging, combined with clinical, laboratory and - omics analyses will facilitate theranostics to accomplish the ultimate goal of personalized medicine. |
| Author | Sharma, Sushil |
| Author_xml | – sequence: 1 givenname: Sushil surname: Sharma fullname: Sharma, Sushil organization: Saint James School of Medicine, Cane Hall, St Vincent, St Vincent & Grenadine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28302035$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj0tLAzEUhYNUtFb_gtRdN6O5eWcpxRdU3dT1cDOTlEAmqfNY9N9bsIKrcxYfh_NdkVku2RNyB_SegRYPwI0VkgIYpRRoykECgBTsjMzBaF5JadnsX78gl8xwyiiXc7La9piHhGMsGdPyfUpj7EqLKY6H5Yef-hI73MW8uybnAdPgb065IF_PT9v1a7X5fHlbP24qJzSMlQitUMppagN3EBiqpvEc2gBoA3PWWSsbNAy4dix4NJJz4TBgEG2jnGELsvrd3ffle_LDWHdxaHxKmH2ZhvqoYQxYw-wRvT2hk-t8W-_749f-UP_ZsR_Q7lJi |
| CitedBy_id | crossref_primary_10_3390_nano12142490 crossref_primary_10_1016_j_addicn_2023_100135 crossref_primary_10_1186_s12859_018_2477_7 crossref_primary_10_1016_j_neuroimage_2025_121264 crossref_primary_10_3389_fphar_2023_1177421 crossref_primary_10_1016_j_ijbiomac_2024_136220 crossref_primary_10_1016_j_therap_2020_12_006 |
| ContentType | Journal Article |
| Copyright | Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org. |
| Copyright_xml | – notice: Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.2174/1389450118666170315111542 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| EISSN | 1873-5592 |
| ExternalDocumentID | 28302035 |
| Genre | Journal Article Review |
| GroupedDBID | CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-b471t-4fd466b709f3b1f2a6cce31df1a9f2b9b995ca82137b2fea85334bafaf4dc6b82 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 11 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000402833000006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1873-5592 |
| IngestDate | Fri Jul 11 04:35:21 EDT 2025 Thu Apr 03 07:05:48 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | magnetic resonance imaging (MRI) ultrasound imaging radiopharmaceuticals nanoparticles Computerized tomography (CT) personalized theranostics positron emission tomography (PET) magnetic resonance spectroscopy (MRS) |
| Language | English |
| License | Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b471t-4fd466b709f3b1f2a6cce31df1a9f2b9b995ca82137b2fea85334bafaf4dc6b82 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 28302035 |
| PQID | 1878819829 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1878819829 pubmed_primary_28302035 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-07-01 |
| PublicationDateYYYYMMDD | 2017-07-01 |
| PublicationDate_xml | – month: 07 year: 2017 text: 2017-07-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Current drug targets |
| PublicationTitleAlternate | Curr Drug Targets |
| PublicationYear | 2017 |
| Score | 2.2395544 |
| SecondaryResourceType | review_article |
| Snippet | Recently high-resolution, noninvasive, multimodality in-vivo molecular imaging with PET, SPECT, CT and MRI, employing fusion algorithms has revolutionized... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1039 |
| SubjectTerms | Animals Apoptosis - radiation effects Brain - metabolism Central Nervous System Infections - diagnostic imaging Glucose - metabolism Humans Mice Mice, Inbred C57BL Multimodal Imaging Neurodegenerative Diseases - diagnostic imaging Radioligand Assay Receptors, Nicotinic - metabolism Stem Cell Transplantation Substance-Related Disorders - diagnostic imaging Translational Medical Research |
| Title | Translational Multimodality Neuroimaging |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28302035 https://www.proquest.com/docview/1878819829 |
| Volume | 18 |
| WOSCitedRecordID | wos000402833000006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEB7Uinjxga_6YgsevIRuHvvISUQsXiw9KPS2ZLIJFOy22urvd5Ju8SQIXva2sJmZzXzM4_sAbqywIpfOMJkpyRQ5nWkvcmYzRGsdRXSNUWyiGA7L8ViP2oLboh2rXN-J8aKuZzbUyPu8DMTnuhT6bv7OgmpU6K62Ehqb0JEEZUJUF-O4_VYWkhFYFjvQC9POhLv7oSWnsrBpSZCdB952AhuEIMTv4DImmcH-fz_vAPZaeJncr-LhEDZccwS3MSG9tWW_JO7cTmd1ROBJZOeYTKNY0TG8Dh5fHp5Yq5DAkJLKkilfqzzHItVeIvfC5GRfyWvPDVkcNWqdWVMKLgsU3pkyLN6i8car2uZYihPYamaNO4MEU-8L4VHWKSqOGXKUXKSefCVU4bIu9NYHrygCQ1vBNG72uah-jt6F05X1qvmKKqOK9GKpzM7_8PYF7IqQM-Ms7CV0PP1_7gq27ddysvi4jq6l53D0_A0LP67q |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Translational+Multimodality+Neuroimaging&rft.jtitle=Current+drug+targets&rft.au=Sharma%2C+Sushil&rft.date=2017-07-01&rft.issn=1873-5592&rft.eissn=1873-5592&rft.volume=18&rft.issue=9&rft.spage=1039&rft_id=info:doi/10.2174%2F1389450118666170315111542&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1873-5592&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1873-5592&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1873-5592&client=summon |